Treatment of NASH with Gemcabene
Methods and formulations to reduce elevated levels of lipids and apolipoprotein B in subjects having type IIb hyperlipidemia. Methods for preventing, delaying or regressing complications of lipid disorders, including; type IIb hyperlipidemia, NAFLD, and NASH. Methods for preventing or delaying primary and secondary cardiovascular events. Kits useful for such methods. Methods for reducing hepatic fibrosis. Methods for reducing plasma fibrinogen levels.
1. A method for treating or preventing hepatic steatosis, comprising administering to a subject in need thereof an effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt or hydrate thereof.
2. The method for treating for preventing hepatic steatosis of claim 1 , wherein the hepatic steatosis is NAFLD, or NASH.
3. The method for treating or preventing hepatic steatosis of claim 1 , wherein the compound is the monocalcium salt of the compound of Formula I.
4. The method for treating or preventing hepatic steatosis of claim 1 , wherein the compound is a hydrate of the monocalcium salt of the compound of Formula I.
5. A method of reducing the accumulation of liver fat in a subject at risk for liver fat accumulation comprising administering the compound of Formula I:
or a pharmaceutically acceptable salt or hydrate thereof, to the subject.
6. The method of reducing the accumulation of liver fat of claim 5 , wherein the compound is the monocalcium salt of the compound of Formula I.
7. The method of reducing the accumulation of liver fat of claim 5 , wherein the compound is a hydrate of the monocalcium salt of the compound of Formula I.
8. The method according to claim 5 , wherein the subject has hepatic steatosis, type IIb hyperlipidemia, or familial combined hyperlipidemia.
9. The method of claim 5 , wherein the daily dose of the compound is from about 50 mg to about 900 mg.
10. The method of claim 5 , wherein the compound is administered in combination with simtuzumab, GS-4997, GS-974, GS-0976, INT-47 obeticholic acid, or cenicriviroc.
11. The method of claim 5 , wherein the subject's risk of developing liver disease is reduced.
12. The method of claim 11 , wherein the liver disease is nonalcoholic steatohepatitis (NASH), or nonalcoholic fatty liver disease (NAFLD), alcoholic hepatic steatosis or primary biliary cirrhosis.
13. The method of claim 5 , wherein the subject has liver disease.
14. The method of claim 13 , wherein the liver disease is nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD) or alcoholic hepatic steatosis.
15. The method of claim 9 , wherein the subject is administered an additional lipid lowering agent.
16. The method of claim 15 , wherein the additional lipid lowering agent is a cholesterol absorption inhibitor, a PCSK9 inhibitor, an ACC inhibitor, an ApoC-III inhibitor, an ACL-inhibitor, prescription fish oil, or a CETP inhibitor.
17. The method of claim 9 , wherein the daily dose the gemcabene is of from about 150 mg to about 600 mg.
18. The method of claim 17 , wherein the compound is administered in combination with a statin.
19. The method of claim 18 , wherein the statin is atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, or pitavastatin.
20. The method of claim 19 , wherein the compound is administered as a fixed dose combination with the statin wherein the daily dose of the compound is 150 mg, 300 mg, 450, or 600 mg; and
i) the statin is atorvastatin and the daily dose of atorvastatin is from 10 mg to 80 mg;
ii) the statin is rosuvastatin and the daily dose of rosuvastatin is from 5 mg to 40 mg;
iii) the statin is simvastatin and the daily dose of simvastatin is from 10 mg to 20 mg;
iv) the statin is pravastatin and the daily dose of pravastatin is from 10 mg to 40 mg;
v) the statin is lovastatin and the daily dose of lovastatin if from 20 mg to 40 mg;
vi) the statin is fluvastatin and the daily dose of fluvastatin is from 20 mg to 40 mg; or
vii) the statin is pitavastatin and the daily dose of pitavastatin is from 1 mg to 3 mg.